SPC
ARNA

Slate Path Capital’s Arena Pharmaceuticals Inc ARNA Stock Holding History

Slate Path Capital’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-215,000
Closed -$9.64M – 32
2019
Q1 		$9.64M Buy
+215,000
New +$9.86M 0.78% 14

Other funds holding ARNA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Slate Path Capital's ARNA Position: Q2 2019 in Review

Slate Path Capital sold out of Arena Pharmaceuticals Inc (ARNA) in Q2 2019, closing a stake of 215,000 shares — an estimated $9.64M sold.

Slate Path Capital first reported a position in ARNA in Q1 2019 and held it in 1 quarter. The position peaked at $9.64M in Q1 2019. 215 funds tracked by Wall St. Rank hold ARNA as of Q2 2019.

  • Slate Path Capital reported no remaining Arena Pharmaceuticals Inc position as of Q2 2019 after selling out during the quarter.
  • Slate Path Capital sold 215,000 Arena Pharmaceuticals Inc shares in Q2 2019, an estimated $9.64M.
  • Slate Path Capital first reported a position in Arena Pharmaceuticals Inc in Q1 2019 and held it in 1 quarter.
  • Slate Path Capital's Arena Pharmaceuticals Inc position peaked at $9.64M in Q1 2019.
  • 215 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q2 2019.

Based on Slate Path Capital's 13F filing for Q2 2019, filed 14 Aug 2019.